Genetics and pathophysiology of mental retardation

European Journal of Human Genetics

Volumn 14, Issue 6, 2006, Pages 701-713

  Chelly, Jamel ^a   Khelfaoui, Malik ^a   Francis, Fiona ^a   Chérif, Beldjord ^a   Bienvenu, Thierry ^a  

^a INSTITUT COCHIN   (France)

Author keywords

Mental retardation; Neuronal morphogenesis and plasticity; RhoGTPase pathways; XLMR

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MEMBRANE PROTEIN; METABOTROPIC RECEPTOR; METHYL CPG BINDING PROTEIN; METHYL CPG BINDING PROTEIN 2; PROTEIN CDC42; PROTEIN P21; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR;

ADAPTIVE BEHAVIOR; CHROMOSOME DISORDER; CHROMOSOME REARRANGEMENT; CLINICAL FEATURE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DATA BASE; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENETIC IDENTIFICATION; GENETIC PREDISPOSITION; GENOME IMPRINTING; HUMAN; INTELLIGENCE QUOTIENT; INTERPERSONAL COMMUNICATION; MENTAL DEFICIENCY; METABOLIC DISORDER; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MONOGENIC DISORDER; NEUROLOGIC DISEASE; NONHUMAN; ONLINE SYSTEM; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKILL; TELOMERE;

CHROMOSOMES, HUMAN; COGNITION DISORDERS; DATABASES, BIBLIOGRAPHIC; DATABASES, GENETIC; HUMANS; MENTAL RETARDATION; METABOLIC DISEASES; NERVOUS SYSTEM DISEASES; SYNDROME;

EID: 33744498065     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201595     Document Type: Review

References (90)

1. American PsychiaDric Association: Task Force on DSM-IV: diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: American pyschiatric association, 1994.
2. Frints SG, Froyen G, Marynen P, Fryns JP: X-linked mental retardation: vanishing boundaries between non-specific (MRX) and syndromic (MRXS) forms. Clin Genet 2002; 62: 423-432.
3. Chelly J: Breakthroughs in molecular and cellular mechanisms underlying X-linked mental retardation. Hum Mol Genet 1999; 8: 1833-1838.
4. Chelly J, Mandel JL: Monogenic causes of X-linked mental retardation. Nat Rev Genet 2001; 2: 669-680.
5. Ropers HH, Hamel BC: X-linked mental retardation. Nat Rev Genet 2005; 6: 46-57.
6. Chiurazzi P, Tabolacci E, Neri G: X-linked mental retardation (XLMR): from clinical conditions to cloned genes. Crit Rev Clin Lab Sci 2004; 41: 117-158.
7. Stevenson RE, Schwartz CE, Schroer RJ: X-linked mental retardation. New York, Oxford: Oxford University Press, 2000.
8. McLaren J, Bryson SE: Review of recent epidemiological studies of mental retardation: Prevalence, associated disorders, and etiology. Am J Ment Retard 1987; 92: 243-254.
9. Flint J, Knight S: The use of telomere probes to investigate submicroscopic rearrangements associated with mental retardation. Curr Opin Genet Dev 2003; 13: 310-316.
10. Herbst DS, Miller JR: Nonspecific X-liTked mental retardation II: the frequency in British Columbia. Am J Med Genet 1980; 7: 461-469.
11. Fishburn J, Turner G, Daniel A, Brookwell R: The diagnosis and frequency of X-linked conditions in a cohort of moderately retarded males with affected brothers. Am J Med Genet 1983; 14: 713-724.
12. Mandel JL, Chelly J: Monogenic X-Iinked mental retardation: is it as frequent as currently estimated? The paradox of the ARX (Aristaless X) mutations. Eur J Hum Genet 2004; 12: 689-693.
13. Poirier K, Lacombe D, Gilbert-Dussardier B et al: Screening of ARX in mental retardation families: Consequences for the strategy of molecular diagnosis. Neurogenetics 2005; 6: 1-8.
14. Knight SJ, Regan R, Nicod A et al: Subtle chromosomal rearrangements in children with unexplained mental retardation. Lancet 1999; 354: 1676-1681.
15. Flint J, Wilkie AO, Buckle VJ, Winter RM, Holland AJ, McDermid HE: The detection of subtelomeric chromosomal rearrangements in idiopathic mental retardation. Nat Genet 1995; 9: 132-140.
16. Rooms L, Reyniers E, Kooy RF: Subtelomeric rearrangements in the mentally retarded: A comparison of detection methods. Hum Mutat 2005; 25: 513-524.
17. De VrAes BB, Winter R, Schinzel A. van Ravenswaaij-Arts C: Telomeres: a diagnosis at the end of the chromosomes. J Med Genet 2003; 40: 385-398.
18. de Vries BB, White SM, Knight SJ et al: Clinical studies on submicroscopic subtelomeric rearrangements: A checklist. J Med Genet 2001; 38: 145-150.
19. Rodriguez-Revenga L, Badenas C, Sanchez A et al: Cryptic chromosomal rearrangement screening in 30 patients with mental retardation and dysmorphic features. Clin Genet 2004; 65: 17-23.
20. Koolen DA, Nillesen WM, Versteeg MH et al: Screening for subtelomeric rearrangements in 210 patients with unexplained mental retardation using multiplex ligation dependent probe amplification (MLPA). J Med Genet 2004; 41: 892-899.
21. Bocian E, Helias-Rodzewicz Z, Suchenek K et al: Subtelomeric rearrangements: Results from FISH studies in 84 families with idiopathic mental retardation. Med Sci Monit 2004; 10: CR143-151.
22. Van Esch H, Bauters M, Ignatius J et al: Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet 2005; 77: 442-453.
23. Vissers LE, de Vries BB, Osoegawa K et al: Array-based comparative genomic hybridization for the genomewide detection of submicroscopic chromosomal abnormalities. Am J Hum Genet 2003; 73: 1261-1270.
24. Vissers LE, van Ravenswaaij CM, Admiraal R et al: Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet 2004; 36: 955-957.
25. Bi W, Saifi GM, Shaw CJ et al: Mutations of RAI1, a PHD-containing protein, in nondeletion patients with Smith-Magenis syndrome. Hum Genet 2004; 115: 515-524.
26. Morison IM, Ramsay JP, Spencer HG: A census of mammalian imprinting. Trends Genet 2005; 21: 457-465.
27. Nicholls RD: The impact of genomic imprinting for neurobehavioral and developmental disorders. J Clin Invest 2000; 105: 413-418.
28. Walter J, Paulsen M: Imprinting and disease. Semin Cell Dev Biol 2003; 14: 101-110.
29. Petersen MB, Brondum-Nielsen K, Hansen LK, Wulff K: Clinical, cytogenetic, and molecular diagnosis of Angelman syndrome: Estimated prevalence rate in a Danish county. Am J Med Genet 1995; 60: 261-262.
30. Steffenburg S, Gillberg CL, Steffenburg U, Kyllerman M: Autism in Angelman syndrome: A population-based study. Pediatr Neurol 1996; 14: 131-136.
31. Nicholls RD, Knepper JL: Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annu Rev Genomics Hum Genet 2001; 2: 153-175.
32. Inlow JK, Restifo LL: Molecular and comparative genetics of mental retardation. Genetics 2004; 166: 835-881.
33. Lehrke R: Theory of X-linkage of major intellectual traits. Am J Ment Defic 1972; 76: 611-619.
34. Turner G: Intelligence and the X chromosome. Lancet 1996; 347: 1814-1815.
35. Turner G, Partington MW: Genes for intelligence on the X chromosome. J Med Genet 1991; 28: 429.
36. Skuse DH: X-linked genes and mental functioning. Hum Mol Genet 2005; 14 (Spec No. 1): R27-R32.
37. Zechner U, Wilda M, Kehrer-Sawatzki H, Vogel W, Fundele R, Hameister H: A high density of X-linked genes for general cognitive ability: A run-away process shaping human evolution? Trends Genet 2001; 17: 697-701.
38. Francis F, Meyer G, Fallet C et al: Human disorders of cortical development - from past to present. Eur J Neurosci 2006; 23, in press.
39. Bahi N, Friocourt G, Carrie A et al: IL1 receptor accessory protein like, a protein involved in X-linked mental retardation, interacts with Neuronal Calcium Sensor-1 and regulates exocytosis. Hum Mol Genet 2003; 12: 1415-1425.
40. Bagni C, Greenough WT: From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci 2005; 6: 376-387.
41. Koekkoek SK, Yamaguchi K, Milojkovic BA et al: Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in fragile X syndrome. Neuron 2005; 47: 339-352.
42. Schenck A, Bardoni B, Langmann C, Harden N, Mandel JL, Giangrande A: CYFIP/Sra-1 controls neuronal connectivity in Drosophila and links the Rac1 GTPase pathway to the fragile X protein. Neuron 2003; 38: 887-898.
43. Billuart P, Chelly J: From fragile X mental retardation protein to Rac1 GTPase: New insights from Fly CYFIP. Neuron 2003; 38: 843-845.
44. Meng J, Meng Y, Hanna A, Janus C, Jia Z: Abnormal long-lasting synaptic plasticity and cognition in mice lacking the mental retardation gene Pak3. J Neurosci 2005; 25: 6641-6650.
45. Boda B, Alberi S, Nikonenko I et al: The mental retardation protein PAK3 contributes to synapse formation and plasticity in hippocampus. J Neurosci 2004; 24: 10816-10825.
46. Govek EE, Newey SE, Akerman CJ, Cross JR, Van der Veken L, Van Aelst L: The X-linked mental retardation protein oligophrenin-1 is required for dendritic spine morphogenesis. Nat Neurosci 2004; 7: 364-372.
47. Ramakers GJ: Rho proteins, mental retardation and the cellular basis of cognition. Trends Neurosci 2002; 25: 191-199.
48. Jamain S, Quach H, Betancur C et al: Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 2003; 34: 27-29.
49. Laumonnier F, Bonnet-Brilhault F, Gomot M et al: X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet 2004; 74: 552-557.
50. Tarpey P, Parnau J, Blow M et al: Mutations in the DLG3 gene cause nonsyndromic X-linked mental retardation. Am J Hum Genet 2004; 75: 318-324.
51. Carrie A, Jun L, Bienvenu T et al: A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. Nat Genet 1999; 23: 25-31.
52. D'Adamo P, Menegon A, Lo Nigro C et al: Mutations in GDI1 are responsible for X-linked non-specific mental retardation. Nat Genet 1998; 19: 134-139.
53. Bienvenu T, des Portes V, Saint Martin A et al: Non-specific X-linked semidominant mental retardation by mutations in a Rab GDP-dissociation inhibitor. Hum Mol Genet 1998; 7: 1311-1315.
54. Dean C, Scholl FG, Choih J et al: Neurexin mediates the assembly of presynaptic terminals. Nat Neurosci 2003; 6: 708-716.
55. Scheiffele P, Fan J, Choih J, Fetter R, Serafini T: Neuroligin expressed in nonneuronal cells triggers presynaptic development in contacting axons. Cell 2000; 101: 657-669.
56. Geppert M, Goda Y, Stevens CF, Sudhof TC: The small GTP-binding protein Rab3A regulates a late step in synaptic vesicle fusion. Nature 1997; 387: 810-814.
57. Ishizaki H, Miyoshi J, Kamiya H et al: Role of rab GDP dissociation inhibitor alpha in regulating plasticity of hippocampul neurotransmission. Proc Natl Acad Sci USA 2000; 97: 11587-11592.
58. D'Adamo P, Welzl H, Papadimitriou S et al: Deletion of the mental retardation gene Gdi1 impairs associative memory and alters social behavior in mice. Hum Mol Genet 2002; 11: 2567-2580.
59. Kandel ER: The molecular biology ofAmemory storage: a dialogue between genes and synapses. Science 2001; 294: 1030-1038.
60. Costa RM, Federov NB, Kogan JH et al: Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 2002; 415: 526-530.
61. Costa RM, Yang T, Huynh DP et al: Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1. Nat Genet 2001; 27: 399-405.
62. Trivier E, De Cesare D, Jacquot S et al: Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome. Nature 1996; 384: 567-570.
63. De Cesare D, Jacquot S, Hanauer A, Sassone-Corsi P: Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. Proc Natl Acad Sci USA 1998; 95: 12202-12207.
64. Harum KH, Alemi L, Johnston MV: Cognitive impairment in Coffin-Lowry syndrome correlates with reduced RSK2 activation. Neurology 2001; 56: 207-214.
65. Petrij F, Giles RH, Dauwerse HG et al: Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995; 376: 348-351.
66. Swank MW, Sweatt JD: Increased histone acetyltransferase and lysine acetyltransferase activity and biphasic activation of the ERK/RSK cascade in insular cortex during novel taste learning. J Neurosci 2001; 21: 3383-3391.
67. Amir RE, Van den Veyver IB, Schultz R et al: Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol 2000; 47: 670-679.
68. Bienvenu T, Carrie A, de Roux N et al: MECP2 mutations account for most cases of typical forms of Rett syndrome. Hum Mol Genet 2000; 9: 1377-1384.
69. Meloni I, Bruttini M, Longo I et al: A mutation in the rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. Am J Hum Genet 2000; 67: 982-985.
70. Couvert P, Bienvenu T, Aquaviva C et al: MECP2 is highly mutated in X-linked mental retardation. Hum Mol Genet 2001; 10: 941-946.
71. Tao J, Van Esch H, Hagedorn-Greiwe M et al: Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. Am J Hum Genet 2004; 75: 1149-1154.
72. Weaving LS, Christodoulou J, Williamson SL et al: Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am J Hum Genet 2004; 75: 1079-1093.
73. Mari F, Azimonti S, Bertani I et al: CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum Mol Genet 2005; 14: 1935-1946.
74. Kriaucionis S, Bird A: DNA methylation and Rett syndrome. Hum Mol Genet 2003; 12 (Spec No. 2): R221-R227.
75. Caballero IMC Hendrich B: MeCP2 in neurons: closing in on the causes of Rett syndrome. Hum Mol Genet 2005; 14 (Spec No. 1): R19-R26.
76. Nuber UA, Kriaucionis S, Roloff TC et al: Up-regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome. Hum Mol Genet 2005; 14: 2247-2256.
77. Chen RZ, Akbarian S, Tudor M, Jaenisch R: Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 2001; 27: 327-331.
78. Guy J, Hendrich B, Holmes M, Martin JE, Bird A: A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 2001; 27: 322-326.
79. Kishi N, Macklis JD: MECP2 is progressively expressed in postmigratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol Cell Neurosci 2004; 27: 306-321.
80. Matarazzo V, Cohen D, Palmer AM et al: The transcriptional repressor Mecp2 regulates terminal neuronal differentiation. Mol Cell Neurosci 2004; 27: 44-58.
81. Atkins CM, Selcher JC, Petraitis JJ, Trzaskos JM, Sweatt JD: The MAPK cascade is required for mammalian associative learning. Nat Neurosci 1998; 1: 602-609.
82. Butler FM, Miller SP, Lee KH, Pierce T: Teaching mathematics to students with mild-to-moderate mental retardation: A review of the literature. Ment Retard 2001; 39: 20-31.
83. Bat-haee MA: A longitudinal study of active treatment of adaptive skills of individuals with profound mental retardation. Psychol Rep 2001; 89: 345-354.
84. Gruters A, Jenner A, Krude H: Long-term consequences of congenital hypothyroidism in the era of screening programmes. Best Pract Res Clin Endocrinol Metab 2002; 16: 369-382.
85. Dashman T, Sansaricq C: Nutrition in the management of inborn errors of metabolism. Clin Lab Med 1993; 13: 407-432.
86. Levy BD, Serhan CN: Exploring new approaches to the treatment of asthma: potential roles for lipoxins and aspirin-triggered lipid mediators. Drugs Today (Barc) 2003; 39: 373-384.
87. Schulze A, Hess T, Wevers R et al: Creatine deficiency syndrome caused by guanidinoacetate methyltransferase deficiency: Diagnostic tools for a new inborn error of metabolism. J Pediatr 1997; 131: 626-631.
88. Schulze A, Ebinger F, Rating D, Mayatepek E: Improving treatment of guanidinoacetate methyltransferase deficiency: Reduction of guanidinoacetic acid in body fluids by arginine restriction and ornithine supplementation. Mol Genet Metab 2001; 74: 413-419.
89. Alarcon JM, Malleret G, Touzani K et al: Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: A model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 2004; 42: 947-959.
90. McBride SM, Choi CH, Wang Y et al: Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005; 45: 753-764.